It is not true that AIFA opposed the use of a monoclonal antibody against Covid in Italy.
The same agency specifies this in a statement, according to which it is false that, as reported by some newspapers, there was an offer of a free sale by the company of the drug.
"In recent days, some articles have been published in national newspapers in which it gives rise to resistance that Aifa allegedly opposed the use in Italy of a drug, the monoclonal antibody Bamlanivimab, produced by the pharmaceutical company Eli Lilly on the national territory - writes the Agency -, and that the same company would have offered for free without obtaining feedback. These are misleading and unsubstantiated claims. "
LIVE FROM AIFA PRESS CONFERENCE
/ p>